CN105283539A - 用于hla的修饰的方法和组合物 - Google Patents

用于hla的修饰的方法和组合物 Download PDF

Info

Publication number
CN105283539A
CN105283539A CN201480025999.3A CN201480025999A CN105283539A CN 105283539 A CN105283539 A CN 105283539A CN 201480025999 A CN201480025999 A CN 201480025999A CN 105283539 A CN105283539 A CN 105283539A
Authority
CN
China
Prior art keywords
hla
cells
cell
dna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480025999.3A
Other languages
English (en)
Chinese (zh)
Inventor
P·D·格雷戈里
L·J·N·库珀
H·托里开
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangamo Therapeutics Inc
University of Texas System
Original Assignee
University of Texas System
Sangamo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Sangamo Biosciences Inc filed Critical University of Texas System
Publication of CN105283539A publication Critical patent/CN105283539A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
CN201480025999.3A 2013-03-12 2014-03-12 用于hla的修饰的方法和组合物 Pending CN105283539A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361777627P 2013-03-12 2013-03-12
US61/777,627 2013-03-12
PCT/US2014/024660 WO2014165177A1 (en) 2013-03-12 2014-03-12 Methods and compositions for modification of hla

Publications (1)

Publication Number Publication Date
CN105283539A true CN105283539A (zh) 2016-01-27

Family

ID=51659088

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480025999.3A Pending CN105283539A (zh) 2013-03-12 2014-03-12 用于hla的修饰的方法和组合物

Country Status (9)

Country Link
US (3) US20150037304A1 (enExample)
EP (1) EP2970886B1 (enExample)
JP (1) JP6433480B2 (enExample)
CN (1) CN105283539A (enExample)
AU (3) AU2014248605B2 (enExample)
CA (1) CA2904210C (enExample)
HK (1) HK1217968A1 (enExample)
IL (1) IL241112B (enExample)
WO (1) WO2014165177A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
CA2930015A1 (en) 2013-11-07 2015-05-14 Editas Medicine, Inc. Crispr-related methods and compositions with governing grnas
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
WO2015164740A1 (en) * 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CN106536721B (zh) * 2014-08-06 2020-12-04 车医科学大学校产学协力团 核酸酶介导的编辑编码hla的基因所产生的免疫相容性细胞
AU2015339743C1 (en) 2014-10-31 2021-04-22 The Trustees Of The University Of Pennsylvania Altering gene expression in modified T cells and uses thereof
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
CN108026526B (zh) * 2015-06-09 2023-05-12 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
CN105112370B (zh) * 2015-08-25 2019-02-05 杭州优善生物科技有限公司 一种体外刺激外周血γδT细胞高效增殖的方法及其应用
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
AU2016362129A1 (en) 2015-12-04 2018-06-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
JP7588390B2 (ja) 2016-10-14 2024-11-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
SG11201907434RA (en) 2017-03-22 2019-10-30 Novartis Ag Compositions and methods for immunooncology
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
AU2018292181B2 (en) 2017-06-30 2025-04-10 Cellectis Cellular immunotherapy for repetitive administration
JP2020534795A (ja) 2017-07-28 2020-12-03 プレジデント アンド フェローズ オブ ハーバード カレッジ ファージによって支援される連続的進化（ｐａｃｅ）を用いて塩基編集因子を進化させるための方法および組成物
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US10785574B2 (en) 2017-12-14 2020-09-22 Flodesign Sonics, Inc. Acoustic transducer driver and controller
WO2019118949A1 (en) 2017-12-15 2019-06-20 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
SG11202007563XA (en) * 2018-02-16 2020-09-29 Univ Kyoto Method for producing low-antigenic cell
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
US11016874B2 (en) 2018-09-19 2021-05-25 International Business Machines Corporation Updating taint tags based on runtime behavior profiles
US10883084B2 (en) 2018-10-05 2021-01-05 Xenotherapeutics, Inc. Personalized cells, tissues, and organs for transplantation from a humanized, bespoke, designated-pathogen free, (non-human) donor and methods and products relating to same
JP7431837B2 (ja) 2018-10-05 2024-02-15 ゼノセラピューティクス インコーポレイテッド 異種移植製品及び異種移植方法
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020097188A1 (en) * 2018-11-06 2020-05-14 Sangamo Therapeutics, Inc. Identification of molecules for inhibition of nk-mediated cell killing
JP2022513490A (ja) * 2018-12-16 2022-02-08 フィジーン、エルエルシー 遺伝子編集線維芽細胞の治療的使用
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
EP3942042A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
JP2020108405A (ja) * 2020-04-03 2020-07-16 米満　吉和 高活性ｎｋ細胞、およびその利用
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
JP2025539410A (ja) * 2022-11-28 2025-12-05 インベクティス，インコーポレイティド ヒト化抗ｈｌａ－ｇキメラ抗原受容体及びそれらの使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120060230A1 (en) * 2010-07-21 2012-03-08 Trevor Collingwood Methods and compositions for modification of a hla locus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
WO2010107493A2 (en) * 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120060230A1 (en) * 2010-07-21 2012-03-08 Trevor Collingwood Methods and compositions for modification of a hla locus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FRANCISCO BORREGO等: "Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis", 《THE JOURNAL OF EXPERIMENTAL MEDICINE》 *
NATHALIE ROUAS-FREISS等: "The immunotolerance role of HLA-G", 《CANCER BIOLOGY》 *
PETER PARHAM: "MHC CLASS I MOLECULES AND KIRS IN HUMAN HISTORY,HEALTH AND SURVIVAL", 《NATURE REVIEWS IMMUNOLOGY》 *

Also Published As

Publication number Publication date
CA2904210C (en) 2022-07-19
US20170216358A1 (en) 2017-08-03
WO2014165177A1 (en) 2014-10-09
JP2016513460A (ja) 2016-05-16
IL241112B (en) 2021-02-28
CA2904210A1 (en) 2014-10-09
EP2970886A4 (en) 2016-08-17
AU2014248605A1 (en) 2015-09-24
HK1217968A1 (zh) 2017-01-27
AU2020203765A1 (en) 2020-06-25
EP2970886B1 (en) 2018-05-23
US20150037304A1 (en) 2015-02-05
JP6433480B2 (ja) 2018-12-05
AU2022211891A1 (en) 2022-09-01
AU2014248605B2 (en) 2020-05-28
IL241112A0 (en) 2015-11-30
EP2970886A1 (en) 2016-01-20
US20220202858A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
JP7462699B2 (ja) Ｔ細胞受容体の標的化破壊
JP7541550B2 (ja) Ｍｈｃ細胞受容体の標的化破壊
US20220202858A1 (en) Methods and compositions for modification of hla
JP6050230B2 (ja) Ｈｌａ遺伝子座の修飾のための方法及び組成物
JP7482176B2 (ja) Ｔ細胞および／またはｈｌａ受容体の標的化破壊
HK1260200B (zh) Mhc细胞受体的靶向破坏

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1217968

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1217968

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20160127